Maximising Pharma Patent Lifecycles 2012
October 10 - 11, 2012
Nueva York NY , Estados Unidos
ATTEND THE ONE EVENT WHICH HAS REMAINED “THE INDUSTRY CONSTANT” FOR SHAPING POLICIES AND STRATEGIES FOR BRAND NAMES AND GENERICS.
Unprecedented patent losses on small molecule pharmaceutical products having values in excess of $100 billion annually will occur in the next few years.
The pharmaceutical industry now stands on the edge of the patent cliff. By 2016, patents on myriad block buster pharmaceutical products for treating ailments and conditions ranging from asthma to high cholesterol to psychosis and beyond will go off patent. In addition, for the first time, US filers must engage in a race to the PTO under the America Invents Act’s first-to-file system, contend with global prior art, and prepare for battle in new PTO proceedings designed to challenge patents during and after the patent examination process. Moreover, as the industry digests recently issued FDA guidance on biosimilars, it remains anyone’s guess as to what effect, if any, these new medicinal entities and therapies will have on the patent end game. Now is the time that both brand name and generic companies must rethink the rules of the game and there is not a minute to lose.
Speakers
David G. Adams,Stephen R. Auten,Sandra A. Bresnick,Kenneth J. Burchfiel,Patricia Carson,Brian Coggio,Sandra J.P. Dennis and many more.
Unprecedented patent losses on small molecule pharmaceutical products having values in excess of $100 billion annually will occur in the next few years.
The pharmaceutical industry now stands on the edge of the patent cliff. By 2016, patents on myriad block buster pharmaceutical products for treating ailments and conditions ranging from asthma to high cholesterol to psychosis and beyond will go off patent. In addition, for the first time, US filers must engage in a race to the PTO under the America Invents Act’s first-to-file system, contend with global prior art, and prepare for battle in new PTO proceedings designed to challenge patents during and after the patent examination process. Moreover, as the industry digests recently issued FDA guidance on biosimilars, it remains anyone’s guess as to what effect, if any, these new medicinal entities and therapies will have on the patent end game. Now is the time that both brand name and generic companies must rethink the rules of the game and there is not a minute to lose.
Speakers
David G. Adams,Stephen R. Auten,Sandra A. Bresnick,Kenneth J. Burchfiel,Patricia Carson,Brian Coggio,Sandra J.P. Dennis and many more.
Eventos relacionados
Maximising Pharma Patent Lifecycles October 10 - 11, 2012
Maximising Pharma Patent Lifecycles 5 October, 2011
Maximising Pharma Patent Lifecycles 15 May, 2010
